Seegene Inc operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seegene Inc with three other
pharmaceutical manufacturers in Asia:
Guangdong Hybribio Biotech Co Ltd
sales of 398.30 million Chinese Renmimbi [US$61.66 million]
(1.74 billion Taiwanese Dollars [US$58.72 million]
of which 100%
was Manufacturing Medical Equipment & Medica), and
Apex Biotechnology Corporation
based in Taiwan
(1.76 billion Taiwanese Dollars [US$59.49 million]
Seegene Inc reported sales of 73.69 billion Korean Won (US$69.20 million)
December of 2016.
increase of 13.1%
versus 2015, when the company's sales were 65.14 billion Korean Won.
Sales at Seegene Inc have increased during each of the previous five years
(and since 2011, sales have increased a total of 87%).